FDA Approves Bimzelx for Plaque Psoriasis: A New Hope for Patients as of October 17, 2023

by B Jamerson | Jul 23, 2024 | 2023 Approvals, Drug approvals, Trending News

What is Bimzelx prescribed for?  Bimzelx is prescribed to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. What is Bimzelx and what does it do? Bimzelx, pronounced bim zel’ ex, (generic name:...

FDA Approves Zilbrysq for Myasthenia Gravis on October 17, 2023

by B Jamerson | Jul 23, 2024 | 2023 Approvals, Drug approvals

What is Zilbrysq prescribed for?   Zilbrysq is prescribed to treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive. What is Zilbrysq and what does it do? Zilbrysq, pronounced zIL-brisk, (generic name:...

FDA Approves Velsipity for Ulcerative Colitis Treatment on October 13, 2023

by B Jamerson | Jul 23, 2024 | 2023 Approvals, Drug approvals

What is Velsipity prescribed for?  Velsipity is prescribed to treat moderately to severely active ulcerative colitis in adults. What is the name of the drug and what does it do? Velsipity, pronounced Vel-sip-itee, (generic name: etrasimod) is a new medication...

FDA Approves Rivfloza for Late-Onset Pompe Disease on September 28, 2023

by B Jamerson | Jul 23, 2024 | 2023 Approvals, Drug approvals

What is Rivfloza prescribed for?   Rivfloza is used to treat Late-Onset Pompe Disease, a rare condition where the body can’t break down sugar properly due to a missing enzyme. This causes sugar to build up in the muscles, leading to muscle weakness and...

FDA Approves DAYBUE for Treating Rett Syndrome Symptoms on March 10, 2023

by B Jamerson | Jul 23, 2024 | 2023 Approvals, Drug approvals

What is DAYBUE prescribed for?   DAYBUE (generic name: trofinetide), pronounced “day-BYOO,” is indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older. What is the name of the drug and what does it do? ...